JP2020515643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515643A5 JP2020515643A5 JP2020502768A JP2020502768A JP2020515643A5 JP 2020515643 A5 JP2020515643 A5 JP 2020515643A5 JP 2020502768 A JP2020502768 A JP 2020502768A JP 2020502768 A JP2020502768 A JP 2020502768A JP 2020515643 A5 JP2020515643 A5 JP 2020515643A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- binding
- use according
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100031506 Complement C5 Human genes 0.000 claims 15
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 208000002874 Acne Vulgaris Diseases 0.000 claims 9
- 206010000496 acne Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 206010000269 abscess Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 210000000106 sweat gland Anatomy 0.000 claims 8
- 210000000440 neutrophil Anatomy 0.000 claims 7
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 6
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 claims 6
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims 6
- 208000010265 Sweet syndrome Diseases 0.000 claims 6
- 206010053555 Arthritis bacterial Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000006311 Pyoderma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 208000002557 hidradenitis Diseases 0.000 claims 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 102100032996 C5a anaphylatoxin chemotactic receptor 2 Human genes 0.000 claims 1
- 102000003712 Complement factor B Human genes 0.000 claims 1
- 108090000056 Complement factor B Proteins 0.000 claims 1
- 108091008102 DNA aptamers Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000017415 Functional neutrophil defect Diseases 0.000 claims 1
- 101000868001 Homo sapiens C5a anaphylatoxin chemotactic receptor 2 Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000033809 Suppuration Diseases 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- PUKBOVABABRILL-YZNIXAGQSA-N avacopan Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1NC(=O)[C@@H]1[C@H](C=2C=CC(NC3CCCC3)=CC=2)N(C(=O)C=2C(=CC=CC=2C)F)CCC1 PUKBOVABABRILL-YZNIXAGQSA-N 0.000 claims 1
- 229950001740 avacopan Drugs 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 229950009686 mirococept Drugs 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127667A JP2022176946A (ja) | 2017-04-03 | 2022-08-10 | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164573 | 2017-04-03 | ||
| EP17164573.2 | 2017-04-03 | ||
| EP17177657.8 | 2017-06-23 | ||
| EP17177657 | 2017-06-23 | ||
| EP17189938 | 2017-09-07 | ||
| EP17189938.8 | 2017-09-07 | ||
| PCT/EP2018/050146 WO2018184739A1 (en) | 2017-04-03 | 2018-01-03 | Treatment of inflammatory diseases with inhibitors of c5a activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127667A Division JP2022176946A (ja) | 2017-04-03 | 2022-08-10 | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515643A JP2020515643A (ja) | 2020-05-28 |
| JP2020515643A5 true JP2020515643A5 (enExample) | 2021-01-07 |
| JP7486415B2 JP7486415B2 (ja) | 2024-05-17 |
Family
ID=61024731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502768A Active JP7486415B2 (ja) | 2017-04-03 | 2018-01-03 | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
| JP2022127667A Withdrawn JP2022176946A (ja) | 2017-04-03 | 2022-08-10 | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127667A Withdrawn JP2022176946A (ja) | 2017-04-03 | 2022-08-10 | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11273225B2 (enExample) |
| EP (3) | EP3411400B1 (enExample) |
| JP (2) | JP7486415B2 (enExample) |
| KR (1) | KR20190138806A (enExample) |
| CN (1) | CN111108118A (enExample) |
| AU (1) | AU2018249310A1 (enExample) |
| CA (1) | CA3058023A1 (enExample) |
| CL (1) | CL2018002698A1 (enExample) |
| DK (1) | DK3411400T3 (enExample) |
| ES (1) | ES2893769T3 (enExample) |
| IL (1) | IL261809B2 (enExample) |
| MX (1) | MX2019011825A (enExample) |
| PL (1) | PL3411400T3 (enExample) |
| SG (1) | SG11201807998WA (enExample) |
| TW (2) | TW202348249A (enExample) |
| WO (1) | WO2018184739A1 (enExample) |
| ZA (1) | ZA201906485B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| PL3411400T3 (pl) * | 2017-04-03 | 2021-12-20 | Inflarx Gmbh | Leczenie chorób zapalnych za pomocą inhibitorów aktywności c5a |
| JP7502865B2 (ja) * | 2017-06-23 | 2024-06-19 | インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
| PL3886820T3 (pl) | 2018-11-30 | 2023-08-14 | Chemocentryx, Inc. | Postacie użytkowe będące kapsułkami |
| CN113543796A (zh) * | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
| WO2020182384A1 (en) | 2019-03-11 | 2020-09-17 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
| US20220211799A1 (en) * | 2019-04-24 | 2022-07-07 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| EP4196501A1 (en) * | 2020-08-12 | 2023-06-21 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
| WO2022093971A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| CN116036233A (zh) * | 2023-01-10 | 2023-05-02 | 中山大学附属第八医院（深圳福田） | 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AUPR833401A0 (en) | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| PL3385384T3 (pl) | 2004-02-12 | 2021-03-08 | Archemix Llc | Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem |
| US20110301098A1 (en) | 2006-07-21 | 2011-12-08 | Quax Paul H A | Treatment for intimal hyperplasia and related conditions |
| AU2007288118A1 (en) * | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| WO2011056972A2 (en) * | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| ES2577548T3 (es) | 2008-12-22 | 2016-07-15 | Chemocentryx, Inc. | Antagonistas de C5aR |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| US9126939B2 (en) | 2010-06-24 | 2015-09-08 | Pingchen Fan | C5AR antagonists |
| PL2970974T3 (pl) | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
| EP3119802B1 (en) | 2014-03-20 | 2019-12-04 | InflaRx GmbH | Inhibitors of c5a for the treatment of viral pneumonia |
| EP3194596A1 (en) | 2014-09-16 | 2017-07-26 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| JP6479974B2 (ja) | 2014-10-15 | 2019-03-06 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 大規模エクリズマブ産生細胞培養を再現する方法 |
| FR3030515B1 (fr) * | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| US20180142010A1 (en) | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| PL3411400T3 (pl) * | 2017-04-03 | 2021-12-20 | Inflarx Gmbh | Leczenie chorób zapalnych za pomocą inhibitorów aktywności c5a |
| WO2020182384A1 (en) | 2019-03-11 | 2020-09-17 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
-
2018
- 2018-01-03 PL PL18701250T patent/PL3411400T3/pl unknown
- 2018-01-03 MX MX2019011825A patent/MX2019011825A/es unknown
- 2018-01-03 DK DK18701250.5T patent/DK3411400T3/da active
- 2018-01-03 CA CA3058023A patent/CA3058023A1/en active Pending
- 2018-01-03 TW TW112106878A patent/TW202348249A/zh unknown
- 2018-01-03 ES ES18701250T patent/ES2893769T3/es active Active
- 2018-01-03 IL IL261809A patent/IL261809B2/en unknown
- 2018-01-03 JP JP2020502768A patent/JP7486415B2/ja active Active
- 2018-01-03 EP EP18701250.5A patent/EP3411400B1/en active Active
- 2018-01-03 EP EP21197604.8A patent/EP3978523A1/en active Pending
- 2018-01-03 SG SG11201807998WA patent/SG11201807998WA/en unknown
- 2018-01-03 WO PCT/EP2018/050146 patent/WO2018184739A1/en not_active Ceased
- 2018-01-03 CN CN201880037003.9A patent/CN111108118A/zh active Pending
- 2018-01-03 AU AU2018249310A patent/AU2018249310A1/en not_active Abandoned
- 2018-01-03 EP EP23179884.4A patent/EP4272821A3/en active Pending
- 2018-01-03 TW TW107100139A patent/TWI826364B/zh active
- 2018-01-03 KR KR1020197031043A patent/KR20190138806A/ko not_active Ceased
- 2018-06-13 US US16/007,634 patent/US11273225B2/en active Active
- 2018-09-24 CL CL2018002698A patent/CL2018002698A1/es unknown
-
2019
- 2019-10-02 ZA ZA2019/06485A patent/ZA201906485B/en unknown
-
2022
- 2022-08-10 JP JP2022127667A patent/JP2022176946A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515643A5 (enExample) | ||
| JP2020524696A5 (enExample) | ||
| Singh et al. | Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis | |
| Ni et al. | An impaired intrinsic microglial clock system induces neuroinflammatory alterations in the early stage of amyloid precursor protein knock-in mouse brain | |
| Frosch et al. | New insights in systemic juvenile idiopathic arthritis—from pathophysiology to treatment | |
| Frenkel et al. | Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression | |
| Song et al. | Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling | |
| Yin et al. | An immuno-blocking agent targeting IL-1β and IL-17A reduces the lesion of DSS-induced ulcerative colitis in mice | |
| JP2018521667A5 (enExample) | ||
| US20210386855A1 (en) | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist | |
| JP2011184466A5 (enExample) | ||
| JP2010505878A (ja) | 線維症の処置のためのｃｃｒ２アンタゴニスト | |
| JP2017513500A5 (enExample) | ||
| Zheng et al. | Pivotal role of cerebral interleukin-23 during immunologic injury in delayed cerebral ischemia in mice | |
| Nagao et al. | Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody | |
| CN102307899A (zh) | 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂 | |
| De Corso et al. | Thymic Stromal Lymphopoietin (TSLP): evidence in respiratory epithelial-driven diseases including chronic rhinosinusitis with nasal polyps | |
| Peters et al. | Synovial fluid as a complex molecular pool contributing to knee osteoarthritis | |
| CN106459181A (zh) | α‑烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法 | |
| Anderson | Advances in understanding COPD | |
| JP2016531843A5 (enExample) | ||
| US11419883B2 (en) | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes | |
| JP2024512384A (ja) | 汎発型膿疱性乾癬における抗ｉｌ－３６ｒ抗体による処置に関連したバイオマーカー | |
| US20250282859A1 (en) | Use of il-36 inhibitors for the treatment of netherton syndrome | |
| Li et al. | Intranasal delivery of E-selectin reduces atherosclerosis in ApoE−/− mice |